Multidisciplinary approach for locally advanced non‑small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

• Aylen Vanessa Ospina ^[3] ; Mariano Provencio ^[3] ; Sergio Bolufer Nadal ^[4] ; José Luis Campo Cañaveral de la Cruz ^[1] ; Virginia Calvo de Juan ^[1] ; Jose Luis González Larriba ^[5] ; Florentino Hernando Trancho ^[5] ; José Ramón Jarabo Sarceda ^[5] ; Ivan Macía Vidueira ^[6] ; Bartomeu Massutí Sureda ^[7] ; Ernest Nadal ^[8] ; Antonio Álvarez Kindelán ^[9] ; Edel Del Barco Morillo ^[10] ; Reyes Bernabé Caro ^[11] ; Joaquim Bosch Barrera ^[12] ; Joaquin Casal Rubio ^[13] ; Javier de Castro ^[14] ; Ángel Cilleruelo Ramos ^[15] ; Manuel Cobo Dols ^[16] ; Manuel Dómine Gómez ^[2] ; Santiago Figueroa Almánzar ^[17] ; Rosario Garcia Campelo ^[18] ; Amelia Insa Mollá ^[17] ; Unai Jiménez Maestre ^[19] ; Rafael López Castro ^[15] ; Margarita Majem ^[20] ; Elisabeth Martínez Téllez ^[20] ; Alex Martinez Marti ^[21] ; David Sánchez Lorente ^[22]
  1. [1] Hospital Universitario Puerta de Hierro

     Hospital Universitario Puerta de Hierro

     Madrid, España

     
  2. [2] Fundación Jiménez Díaz

     Fundación Jiménez Díaz

     Madrid, España

     
  3. [3] Head of the Oncology Department at the Hospital Universitario Puerta de Hierro. Full Professor of Medicine, Universidad Autónoma de Madrid, C/Manuel de Falla, 1 Majadahonda, 28222 Madrid, Spain
  4. [4] H. General Universitario Dr. Balmis de Alicante, Alicante, Spain
  5. [5] H. Clínico San Carlos, Madrid, Spain
  6. [6] H. Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
  7. [7] H. Universitario Dr Balmis Alicante, Alicante, Spain
  8. [8] ICO Bellvitge, Hospitalet, Barcelona, Spain
  9. [9] H. Reina Sofía, Córdoba, Spain
  10. [10] H. Universitario de Salamanca, Salamanca, Spain
  11. [11] Hospital Virgen Del Rocio, Seville, Spain
  12. [12] ICO, H. Universitario Dr. Josep Trueta, Girona, Spain
  13. [13] H. Universitario Alvaro Cunqueiro, Vigo, Spain
  14. [14] H. Universitario La Paz, Madrid, Spain
  15. [15] H. Clínico Universitario de Valladolid, Valladolid, Spain
  16. [16] H. Regional Universitario Málaga, Malaga, Spain
  17. [17] H. Clínico Universitario de Valencia, Valencia, Spain
  18. [18] H. Universitario A Coruña, A Coruña, Spain
  19. [19] H. Universitario Cruces, Barakaldo, Bizkaia, Spain
  20. [20] H. de la Santa Creu i Sant Pau, Barcelona, Spain
  21. [21] H. Universitari Vall D’hebrón, Barcelona, Spain
  22. [22] H. Clinic de Barcelona, Barcelona, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 7, 2024, págs. 1647-1663
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction Recent advances in the treatment of locally advanced NSCLC have led to changes in the standard of care for this disease. For the selection of the best approach strategy for each patient, it is necessary the homogenization of diagnostic and therapeutic interventions, as well as the promotion of the evaluation of patients by a multidisciplinary oncology team.

    Objective Development of an expert consensus document with suggestions for the approach and treatment of locally advanced NSCLC leaded by Spanish Lung Cancer Group GECP.

    Methods Between March and July 2023, a panel of 28 experts was formed. Using a mixed technique (Delphi/nominal group) under the guidance of a coordinating group, consensus was reached in 4 phases: 1. Literature review and defnition of discussion topics 2. First round of voting 3. Communicating the results and second round of voting 4. Defnition of conclusions in nominal group meeting. Responses were consolidated using medians and interquartile ranges. The threshold for agreement was defned as 85% of the votes.

    Results New and controversial situations regarding the diagnosis and management of locally advanced NSCLC were analyzed and reconciled based on evidence and clinical experience. Discussion issues included: molecular diagnosis and biomarkers, radiologic and surgical diagnosis, mediastinal staging, role of the multidisciplinary thoracic committee, neoadjuvant treatment indications, evaluation of response to neoadjuvant treatment, postoperative evaluation, and follow-up.

    Conclusions Consensus clinical suggestions were generated on the most relevant scenarios such as diagnosis, staging and treatment of locally advanced lung cancer, which will serve to support decision-making in daily practice.